

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

Press Release

AVEXA INVESTOR FORUMS TO BE HELD IN APRIL 2009

Melbourne, Australia, 8 April 2009: Biotechnology company Avexa Limited (ASX: AVX) today announced a series of investor forums in Australia. The forums will provide an opportunity to discuss Avexa's 2009 Rights Issue, in which eligible shareholders will be able to participate, to discuss recent and approaching company milestones, and to address investor questions.

The forums will be held in Adelaide, Melbourne, Sydney and Brisbane, during which Dr Julian Chick, Chief Executive Officer and Dr Jonathan Coates, Chief Scientific Officer will be presenting.

Shareholder forum details (a light lunch will be served at each meeting):

ADELAIDE	Friday 17 April, 2009
12.00pm	Level 1, 70 Hindmarsh Square, Adelaide
MELBOURNE	Monday 20 April, 2009
12.00pm	Level 27, Optus Building, 367 Collins Street, Melbourne
SYDNEY	Tuesday 21 April, 2009
12.00pm	Level 29, ABN AMRO Tower, Cnr Phillip & Bent Streets, Sydney
BRISBANE	Thursday 23 April, 2009
12.00pm	Level 29, Riverside Centre, 123 Eagle Street, Brisbane

Update on apricitabine (ATC)

Apricitabine (ATC) is Avexa's lead compound for the treatment of drug-resistant HIV infections, which is currently in a Phase III clinical trial in HIV patients with NRTI resistance. ATC targets a current unmet medical need that has earned the compound Fast Track status with the U.S. Food and Drug Administration. More than 130 sites have been initiated for the Phase III trial.

The company recently announced positive 96 week data for ATC, as well as the passing of the 16 week time point for the last patient enrolled in the initial two-dose phase of ATC's Phase III trial. This significant event triggers the start of the data analysis for the Week 16 results, which Avexa is expecting to announce in the second quarter of 2009.

Dr Jonathan Coates, Avexa's Chief Scientific Officer, is a former Project Leader for multiple anti-viral programs at GlaxoSmithKline and a co-inventor of anti-viral drug 3TC, one of the best selling anti-HIV drugs in history with over USD \$8 billion in global sales to date.

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

About Avexa

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including apricitabine (ATC), its HIV integrase program, its HCV polymerase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program, ATC, is an anti-HIV drug that has successfully completed the 96 week dosing of its Phase IIb trial and is currently in Phase III trials worldwide.

For more information:

Dr Julian Chick
Chief Executive Officer
+61 3 9208 4300

Dr Jonathan Coates
Chief Scientific Officer
+ 61 3 9208 4300

AU: Investor Relations
Sabrina Antoniou
Blueprint Life Science Group
+ 61 2 9519 5537

US: Investor Relations
Remy Bernarda
Blueprint Life Science Group
+ 1 415 375 3340 x2022

www.avexa.com.au